Version 1
: Received: 9 May 2023 / Approved: 10 May 2023 / Online: 10 May 2023 (11:17:21 CEST)
How to cite:
Dias, L. S.; Alencar, N. M. N.; Mesquita, F. P.; Brito, D. M. D. S.; Ramos, M. V.; Souza, P. F. N. Clinical Data and In Silico Analysis Provided New Insights About COVID-19 Behavior in Smokers. Preprints2023, 2023050747. https://doi.org/10.20944/preprints202305.0747.v1
Dias, L. S.; Alencar, N. M. N.; Mesquita, F. P.; Brito, D. M. D. S.; Ramos, M. V.; Souza, P. F. N. Clinical Data and In Silico Analysis Provided New Insights About COVID-19 Behavior in Smokers. Preprints 2023, 2023050747. https://doi.org/10.20944/preprints202305.0747.v1
Dias, L. S.; Alencar, N. M. N.; Mesquita, F. P.; Brito, D. M. D. S.; Ramos, M. V.; Souza, P. F. N. Clinical Data and In Silico Analysis Provided New Insights About COVID-19 Behavior in Smokers. Preprints2023, 2023050747. https://doi.org/10.20944/preprints202305.0747.v1
APA Style
Dias, L. S., Alencar, N. M. N., Mesquita, F. P., Brito, D. M. D. S., Ramos, M. V., & Souza, P. F. N. (2023). Clinical Data and In <em>Silico</em> Analysis Provided New Insights About COVID-19 Behavior in Smokers. Preprints. https://doi.org/10.20944/preprints202305.0747.v1
Chicago/Turabian Style
Dias, L. S., Márcio Viana Ramos and Pedro Filho Noronha Souza. 2023 "Clinical Data and In <em>Silico</em> Analysis Provided New Insights About COVID-19 Behavior in Smokers" Preprints. https://doi.org/10.20944/preprints202305.0747.v1
Abstract
Here, one hundred patients (50 smokers and 50 non-smokers) clinically diagnosed with COVID-19 were studied. Yet, bioinformatics was used to predict epitopes on Tobacco mosaic virus coat protein (TMV-CP) to produce antibodies towards SARS-CoV-2. Death was three times higher in non-smokers than in smokers. However, biochemical parameters did not separate the groups. Bioinformatics analysis predicted the presence of B-cell epitopes in TMV-CP, suggesting the production of antibodies anti-TMV-CP in smoker patients. Smokers may develop severe forms of COVID-19, but survival was superior in the evaluated group than in non-smokers. Anti-TMV-CP antibodies, potentially present in smokers, might act as a pro-immune agent against SARS-CoV-2 at earlier stages of infection. These data are helpful for future studies assessing COVID-19 in smokers.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.